Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Accumulated Expenses (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Accumulated Expenses for 3 consecutive years, with $21.5 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Accumulated Expenses rose 161.61% year-over-year to $21.5 million, compared with a TTM value of $21.5 million through Sep 2021, up 161.61%, and an annual FY2020 reading of $11.7 million, up 302.9% over the prior year.
  • Accumulated Expenses was $21.5 million for Q3 2021 at Black Diamond Therapeutics, up from $18.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $21.5 million in Q3 2021 and bottomed at $2.5 million in Q1 2020.
  • Average Accumulated Expenses over 3 years is $10.7 million, with a median of $9.9 million recorded in 2020.
  • Peak annual rise in Accumulated Expenses hit 455.08% in 2021, while the deepest fall reached 161.61% in 2021.
  • Year by year, Accumulated Expenses stood at $2.9 million in 2019, then surged by 302.9% to $11.7 million in 2020, then skyrocketed by 84.09% to $21.5 million in 2021.
  • Business Quant data shows Accumulated Expenses for BDTX at $21.5 million in Q3 2021, $18.5 million in Q2 2021, and $14.1 million in Q1 2021.